How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
10
VTGN Quote, Financials, Valuation and Earnings
Last price:
$0.56
Seasonality move
:
-11.81%
Day range:
$0.54 - $0.57
52-week range:
$0.54 - $5.14
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
19.59x
P/B ratio:
0.33x
Volume:
712.4K
Avg. volume:
4.7M
1-year change:
-81.01%
Market cap:
$22M
Revenue:
$486K
EPS (TTM):
-$1.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$139.5K | -$0.49 | -40.39% | -5.71% | $0.97 |
|
DARE
Daré Bioscience, Inc.
|
$765K | -$0.43 | 2911.81% | -13.48% | $10.75 |
|
GOVX
GeoVax Labs, Inc.
|
-- | -- | -100% | -- | $204.63 |
|
OMER
Omeros Corp.
|
-- | $0.16 | -- | -2.38% | $38.00 |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$0.32 | -100% | -3.03% | $4.00 |
|
XOMA
XOMA Royalty Corp.
|
$11.1M | -$0.09 | 27.73% | -80.01% | $64.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$0.56 | $0.97 | $22M | -- | $0.00 | 0% | 19.59x |
|
DARE
Daré Bioscience, Inc.
|
$1.81 | $10.75 | $25.9M | 95.38x | $0.00 | 0% | 365.38x |
|
GOVX
GeoVax Labs, Inc.
|
$2.80 | $204.63 | $4.8M | -- | $0.00 | 0% | 2.88x |
|
OMER
Omeros Corp.
|
$11.69 | $38.00 | $828.8M | -- | $0.00 | 0% | -- |
|
SPRO
Spero Therapeutics, Inc.
|
$2.19 | $4.00 | $123.4M | 10.75x | $0.00 | 0% | 4.15x |
|
XOMA
XOMA Royalty Corp.
|
$25.66 | $64.50 | $317.8M | 34.42x | $0.54 | 0% | 8.92x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
2.73% | 1.873 | 1.35% | 5.66x |
|
DARE
Daré Bioscience, Inc.
|
74.07% | -0.066 | 27.91% | 1.09x |
|
GOVX
GeoVax Labs, Inc.
|
-- | 1.979 | -- | 2.75x |
|
OMER
Omeros Corp.
|
254.22% | -2.814 | 126.5% | 0.76x |
|
SPRO
Spero Therapeutics, Inc.
|
11.23% | 13.382 | 3.17% | 3.63x |
|
XOMA
XOMA Royalty Corp.
|
54.99% | 1.607 | 26.95% | 3.38x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
VTGN
Vistagen Therapeutics, Inc.
|
$73K | -$20.1M | -74.76% | -76.57% | -7772.48% | -$13.8M |
|
DARE
Daré Bioscience, Inc.
|
-$610.6K | -$3.7M | -459.12% | -- | -159660.87% | -$616.8K |
|
GOVX
GeoVax Labs, Inc.
|
-$16.8K | -$6.4M | -433.69% | -433.69% | -635.8% | -$6.2M |
|
OMER
Omeros Corp.
|
-$240K | -$26.4M | -59.56% | -- | -- | -$18.5M |
|
SPRO
Spero Therapeutics, Inc.
|
-- | -$9.7M | -97.58% | -107.04% | -319% | $17.4M |
|
XOMA
XOMA Royalty Corp.
|
$8.5M | -$1.3M | 7.44% | 17.31% | -14.22% | -$957K |
Vistagen Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns VTGN or DARE?
Daré Bioscience, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -154904.35%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Daré Bioscience, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M DAREDaré Bioscience, Inc.-26547.83% -$0.28 $11M -
What do Analysts Say About VTGN or DARE?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 73.18%. On the other hand Daré Bioscience, Inc. has an analysts' consensus of $10.75 which suggests that it could grow by 493.92%. Given that Daré Bioscience, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Daré Bioscience, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 DAREDaré Bioscience, Inc.3 0 0 -
Is VTGN or DARE More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Daré Bioscience, Inc. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.454%.
-
Which is a Better Dividend Stock VTGN or DARE?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Daré Bioscience, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Daré Bioscience, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or DARE?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than Daré Bioscience, Inc. quarterly revenues of $2.3K. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than Daré Bioscience, Inc.'s net income of -$3.6M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Daré Bioscience, Inc.'s PE ratio is 95.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 19.59x versus 365.38x for Daré Bioscience, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M DAREDaré Bioscience, Inc.365.38x 95.38x $2.3K -$3.6M
-
Which has Higher Returns VTGN or GOVX?
GeoVax Labs, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -630.04%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat GeoVax Labs, Inc.'s return on equity of -433.69%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M GOVXGeoVax Labs, Inc.-- -$0.31 $4.9M -
What do Analysts Say About VTGN or GOVX?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 73.18%. On the other hand GeoVax Labs, Inc. has an analysts' consensus of $204.63 which suggests that it could grow by 7208.04%. Given that GeoVax Labs, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe GeoVax Labs, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 GOVXGeoVax Labs, Inc.4 0 0 -
Is VTGN or GOVX More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison GeoVax Labs, Inc. has a beta of 3.675, suggesting its more volatile than the S&P 500 by 267.454%.
-
Which is a Better Dividend Stock VTGN or GOVX?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GeoVax Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. GeoVax Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or GOVX?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than GeoVax Labs, Inc. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than GeoVax Labs, Inc.'s net income of -$6.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while GeoVax Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 19.59x versus 2.88x for GeoVax Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M GOVXGeoVax Labs, Inc.2.88x -- -- -$6.3M
-
Which has Higher Returns VTGN or OMER?
Omeros Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of --. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Omeros Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M OMEROmeros Corp.-- -$0.47 $143M -
What do Analysts Say About VTGN or OMER?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 73.18%. On the other hand Omeros Corp. has an analysts' consensus of $38.00 which suggests that it could grow by 225.06%. Given that Omeros Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Omeros Corp. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 OMEROmeros Corp.2 2 0 -
Is VTGN or OMER More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Omeros Corp. has a beta of 2.380, suggesting its more volatile than the S&P 500 by 138.029%.
-
Which is a Better Dividend Stock VTGN or OMER?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Omeros Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Omeros Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or OMER?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are larger than Omeros Corp. quarterly revenues of --. Vistagen Therapeutics, Inc.'s net income of -$19.4M is higher than Omeros Corp.'s net income of -$21.2M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Omeros Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 19.59x versus -- for Omeros Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M OMEROmeros Corp.-- -- -- -$21.2M
-
Which has Higher Returns VTGN or SPRO?
Spero Therapeutics, Inc. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of -242.19%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat Spero Therapeutics, Inc.'s return on equity of -107.04%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M SPROSpero Therapeutics, Inc.-- -$0.13 $29.8M -
What do Analysts Say About VTGN or SPRO?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 73.18%. On the other hand Spero Therapeutics, Inc. has an analysts' consensus of $4.00 which suggests that it could grow by 82.65%. Given that Spero Therapeutics, Inc. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe Spero Therapeutics, Inc. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 SPROSpero Therapeutics, Inc.0 1 0 -
Is VTGN or SPRO More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison Spero Therapeutics, Inc. has a beta of 1.461, suggesting its more volatile than the S&P 500 by 46.062%.
-
Which is a Better Dividend Stock VTGN or SPRO?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Spero Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. Spero Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios VTGN or SPRO?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than Spero Therapeutics, Inc. quarterly revenues of $3M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than Spero Therapeutics, Inc.'s net income of -$7.4M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while Spero Therapeutics, Inc.'s PE ratio is 10.75x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 19.59x versus 4.15x for Spero Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M SPROSpero Therapeutics, Inc.4.15x 10.75x $3M -$7.4M
-
Which has Higher Returns VTGN or XOMA?
XOMA Royalty Corp. has a net margin of -7525.97% compared to Vistagen Therapeutics, Inc.'s net margin of 52.48%. Vistagen Therapeutics, Inc.'s return on equity of -76.57% beat XOMA Royalty Corp.'s return on equity of 17.31%.
Company Gross Margin Earnings Per Share Invested Capital VTGNVistagen Therapeutics, Inc.28.3% -$0.54 $68.2M XOMAXOMA Royalty Corp.90.59% $0.70 $239.9M -
What do Analysts Say About VTGN or XOMA?
Vistagen Therapeutics, Inc. has a consensus price target of $0.97, signalling upside risk potential of 73.18%. On the other hand XOMA Royalty Corp. has an analysts' consensus of $64.50 which suggests that it could grow by 151.36%. Given that XOMA Royalty Corp. has higher upside potential than Vistagen Therapeutics, Inc., analysts believe XOMA Royalty Corp. is more attractive than Vistagen Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings VTGNVistagen Therapeutics, Inc.0 5 0 XOMAXOMA Royalty Corp.4 0 0 -
Is VTGN or XOMA More Risky?
Vistagen Therapeutics, Inc. has a beta of 0.307, which suggesting that the stock is 69.277% less volatile than S&P 500. In comparison XOMA Royalty Corp. has a beta of 0.889, suggesting its less volatile than the S&P 500 by 11.101%.
-
Which is a Better Dividend Stock VTGN or XOMA?
Vistagen Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XOMA Royalty Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.54 per share. Vistagen Therapeutics, Inc. pays -- of its earnings as a dividend. XOMA Royalty Corp. pays out 39.59% of its earnings as a dividend. XOMA Royalty Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios VTGN or XOMA?
Vistagen Therapeutics, Inc. quarterly revenues are $258K, which are smaller than XOMA Royalty Corp. quarterly revenues of $9.4M. Vistagen Therapeutics, Inc.'s net income of -$19.4M is lower than XOMA Royalty Corp.'s net income of $10.3M. Notably, Vistagen Therapeutics, Inc.'s price-to-earnings ratio is -- while XOMA Royalty Corp.'s PE ratio is 34.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics, Inc. is 19.59x versus 8.92x for XOMA Royalty Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income VTGNVistagen Therapeutics, Inc.19.59x -- $258K -$19.4M XOMAXOMA Royalty Corp.8.92x 34.42x $9.4M $10.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Sell
50
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Sell
40
GDXU alert for Jan 31
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Sell
34
PFSI alert for Jan 31
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Sell
40
SHNY alert for Jan 31
MicroSectors Gold 3X Leveraged ETN [SHNY] is down 31.56% over the past day.
